GMTX - Shares of Gemini Therapeutics Inc. (GMTX) Surpass 52-Week Low
Gemini Therapeutics Inc. (NASDAQ:GMTX) traded at a new 52-week low today of $6.40. This new low was reached on above average trading volume as 660,000 shares traded hands, while the average 30-day volume is approximately 197,000 shares.
Gemini Therapeutics Inc. (NASDAQ:GMTX) is currently priced 90.4% above its average consensus analyst price target of $0.62.
Gemini Therapeutics Inc is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health.
In the past 52 weeks, shares of Gemini Therapeutics Inc. have traded between the current low of $6.40 and a high of $19.09 and is now at $6.50.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer